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The purpose of this study is to compare the safety and effectiveness of BMS versus 
DES in the coronary artery using unconventional and potentially more efficient post-
market surveillance methods. A retrospective cohort study was conducted of 217,654 
Medicare, Medicaid, and private insurance beneficiaries ages 41 years and older who 
were treated with coronary stenting between January 2007 and December 2010. 
Compared to BMS, DES use was associated with a significant reduction of 
myocardial infarction (Hazard Ratio (HR): 0.811; CI: [0.774, 0.84]), coronary artery 
bypass graft (HR 0.627; CI: [0.590, 0.666]), and repeat percutaneous coronary 
intervention (HR 0.910; CI: [0.888, 0.933]) at a median follow-up of 659 days. Use of 
DES was associated with superior CHD outcomes compared to BMS regardless of 
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Coronary heart disease (CHD) caused approximately 1 out of every 7 deaths in 
the United States in 2011 and is expected to account for more than 23.6 million deaths 
per year by 2030 due to the obesity epidemic (Mozaffarian et al., 2015). Each year, 
635,000 Americans experience a coronary attack for the first time, 300,000 have a 
recurrent attack, and an additional 155,000 experience silent first attacks (Mozaffarian et 
al., 2015).  CHD is estimated to cost $320.1 billion per year in the U.S., with $195.6 
billion in direct costs (i.e., hospital services, prescribed medications, home health care) 
and $124.5 billion in indirect costs (i.e., lost future productivity due to death). The annual 
cost of CHD is projected to rise to $1.13 trillion by 2030. 
Coronary stents and balloon angioplasty, or percutaneous coronary intervention 
(PCI), are widely used procedures for patients with multi-vessel coronary artery disease. 
Stents are wire meshes placed in occluded arteries to prevent sudden closure of the artery. 
There are two main types of coronary stents: bare-metal and drug-eluting. A bare-metal 
stent (BMS) is a small, metal mesh tube that is permanently inserted to prevent the artery 
from closing up. Drug-eluting stents (DES) contain a polymer coating of antiproliferative 
agents that are intended to prevent the artery from closing in the long term. Shortly after 
the introduction of DES in April 2003, DES were used in 90% of lesions, but afterwards 
DES decreased to 64% of all stents according to the National Cardiovascular Data 
Registry (Krone et al., 2010). In the US, DES are now implanted in more than 500,000 





Between 2000 and 2010, the annual number of inpatient cardiovascular 
procedures (e.g., CABG, PCI) increased by 28% to 7,588,000 (Mozaffarian et al., 2015).  
The coronary stent market c is predicted to continue to increase in value from $4.89 
billion in 2013 to $5.62 billion by 2020 (GlobalHealth, 2014). Given that DES cost about 
$1,846 more than BMS to manufacture and implant (Schafer et al., 2011) due to the 
unique biomaterial properties of DES, it is important to examine the cost effectiveness of 
these more expensive stent technologies. 
In several studies, the implantation of DES resulted in lower rates of repeat 
revascularization, but did not show an advantage in mortality or recurrent myocardial 
infarction (MI) when compared to BMS (Laarman et al., 2006; Luca et al., 2009; 
Spaulding et al., 2006; Stone et al., 2009). Other CHD outcomes of interest include stent 
thrombosis (ST), the blockage of a stented vein or artery due to a clot, and very late stent 
thrombosis (VLST), the clotting of stented area over a year after the initial stent 
implantation procedure. Two studies found that VLST was more frequent among patients 
with DES (Brodie et al., 2011; Vink et al., 2011). In one of these studies, VLST was 
found almost exclusively after DES implantation (Brodie et al., 2011). DES patients who 
have experienced an AMI and have a history of ischemia have increased risk of ST or 
adverse side effects of antiplatelet agents (Fujimoto et al., 2008).  
Reports from large registries and meta-analyses of randomized trials present 
inconclusive evidence of increased ST risk in DES (Douglas et al., 2009; Epstein, 
Ketcham, Rathore, & Groeneveld, 2012; Federspiel et al., 2012). ST after BMS typically 
occurs within the first 30 days after implantation, but VLST after DES can occur years 





coronary artery disease and 0.4% to 0.6% after unrestricted use (Kirtane & Stone, 2011).  
More mechanistic, large-scale and long-term studies are therefore needed, especially by 
race and gender.  
While randomized clinical trials may continue serving as the gold standard for 
comparing alternative treatments, observational studies offer a more cost-effective 
alternative to move research forward, particularly in light of recommendations to 
prioritize post market surveillance and detect long term effects of medical devices as 
early as possible. Among three previous observational studies that used administrative 
claims data, none found a decrease in unadjusted mortality risks for DES (Douglas et al., 
2009; Federspiel et al., 2012; Malenka, Kaplan, Lucas, Sharp, & Skinner, 2008). Two of 
these studies found that DES led to a small decrease in ST-elevation myocardial 
infarction(Douglas et al., 2009; Malenka et al., 2008). Federspiel et al. (2012) examined 
DES and BMS effectiveness in 62,309 fee-for-service beneficiaries right around the time 
that DES were first introduced to the market (between 2003 and 2004), which may have 
influenced the types of patients who were receiving DES versus BMS.  
Significant challenges remain in understanding racial and gender differences in 
cardiovascular risk factors and inclusion of racial/ethnic minority groups in clinical trials 
of therapeutic interventions (Ferdinand, 2006).  Racial and gender disparities have also 
been noted in the response to stent type; however, due to limited data on racial/ethnic 
minorities receiving PCI, there is no conclusive evidence (Berger, Sanborn, Sherman, & 
Brown, 2004; Collins et al., 2010; Marks, Mensah, Kennard, Detre, & Jr, 2000; Maynard, 





This thesis examined safety and effectiveness of DES versus BMS coronary stents 
among a sample of healthcare beneficiaries enrolled in the Multi-Payer Claims Database 
(MPCD) for at least 6 months to capture a larger demographic than pervious surveillance 
studies. A subset of claims data for beneficiaries who underwent a stent implantation 
between January 2007 and December 2010 was included in this analysis. 
The MPCD is a combination of OptumInsights’s Normative Health Information 
(NHI) group coverage database and a 15% sample of Medicare and Medicaid claims. 
Other analyses have used similar national claims databases (e.g., Medicare inpatient fee-
for-service claims files) to compare the effectiveness of DES and BMS. However, the 
mean age of patients who received BMS and DES in 2009 were 65 and 64.4 years, 
respectively (Auerbach, Maeda, & Steiner, 2012). The majority of these patients would 
not have been included in previous studies limited to Medicare patients at least 66 years 
of age  (Douglas et al., 2009; Federspiel et al., 2012). The MPCD offers the opportunity 
to look at CHD outcomes in younger patients because of the inclusion of NHI claims. 
Use of this private and public health insurance database may therefore reveal a more 






II. SPECIFIC AIMS  
The specific aims of the proposed study are to: 
1)  Compare effectiveness of DES versus BMS stents in preventing CHD outcomes 
for patients in a nationwide sample. 
2) Determine whether the association between CHD outcomes and stent type varies 
by race. 
3) Determine whether the association between CHD outcomes and stent type varies 
by gender. 
The null hypotheses are that no difference exists between the safety and effectiveness 
of BMS and DES, and by race or gender. Given how commonly these permanent 
implants are used, it is critical to understand the comparative effectiveness and safety of 








Drug-eluting and Bare-metal Coronary Stents 
In acute ST-segment elevation myocardial infarction, stenting has been shown to 
be the optimal treatment compared with medical therapy or angioplasty alone (Luca et 
al., 2008). Originally, bare-metal stents (BMS) improved procedural safety and no longer 
required a standby surgeon for this complex treatment after implantation. However, BMS 
implantation may lead to neointimal hyperplasia, restenosis, and the need for repeat 
revascularization. Stent thrombosis (ST) is an injury response that involves vascular 
smooth muscle cell migration and proliferation and proteoglycan deposition; it is an 
uncommon but serious complication that almost always presents as death or a large non-
fatal myocardial infarction (MI) (Stone et al., 2007). This injury response is mainly 
responsible for restenosis after BMS implantation. This prompted the development of 
DES, which were designed to release pharmacological agents to inhibit the response to 
injury. Drugs released from DES (i.e., Paxitol, Sirulimus) have biological effects such as 
activation of signal transduction pathways and inhibition of cell proliferation (Lüscher et 
al., 2007). Farb (2003) found that DES offered significantly lower percentage 
endothelialization. The introduction of DES reduced the rates of restenosis and target-
vessel revascularization to below 10%, based on initial clinical trials (Morice et al., 2002; 
Moses et al., 2003). Most thrombosis events occur within the first 10 days after 
implantation and it is rare to observe ST after the first month (Farb et al., 2003; Joner et 
al., 2006). 





Although BMS and DES have proven to be a safe and effective treatment, their 
use may result in ST. ST can block the free flow of blood through an artery and cause a 
heart attack or even death. Recent studies have presented conflicting results as to the risk 
of ST with certain DES. Randomized clinical trials have not demonstrated an increased 
event-free probability of DES over BMS (Moses et al., 2003; Stone et al., 2004). 
However, several observational analyses suggest a higher event-free probability among 
patients with DES (Douglas et al., 2009; Mauri et al., 2008; Ogita et al., 2009; Tu et al., 
2007). In several analyses, patients who received DES experienced a 23-25% relative 
reduction in subsequent myocardial infarction (Douglas et al., 2009; Hannan et al., 2007; 
Malenka et al., 2008; Stettler et al., 2007). In contrast, Brodie et al. found that VLST and 
reinfarction (>1 year) were more frequent with DES(2011). Another follow-up study 
found VLST almost exclusively after the use of DES (Vink et al., 2011). In addition, no 
difference in the incidence of definite or probable ST was seen, although very late ST 
was almost exclusively seen after the use of DES. The exact pathogenesis of ST is not 
fully understood; it may involve factors such as procedure-related factors, patient-related 
factors, and lesion characteristics.  
It is difficult to measure CHD outcomes due to the long period of follow-up and 
experimental procedure that is required to accurately detect the effects of ST. The CHD 
outcomes of interest in this thesis include: acute myocardial infarction (AMI), repeat 
percutaneous intervention, and coronary artery bypass graft (CABG). AMI is an acute 
coronary syndrome that can occur during the unstable periods of coronary 
atherosclerosis. Progression of atherosclerosis is triggered and enhanced by several 





minor in chronic disease and clinically silent for years, but may also be catastrophic and 
lead to sudden death or severe vasculature damage. AMI can be the first sign of CHD or 
may occur repeatedly in patients with chronic disease (Thygesen, 2007). 
Treatment adherence is an important factor in ST pathogenesis. The 2006 
American College of Cardiology Foundation/American Heart Association Task Force on 
Practice Guidelines recommends that “after the PCI procedure, in patients with neither 
aspirin resistance, allergy, nor increased risk of bleeding, aspirin 325 mg daily should be 
given for at least 1 month after bare-metal stent implantation, 3 months after sirolimus-
eluting stent implantation, and 6 months after paclitaxel-eluting stent implantation, after 
which daily chronic aspirin use should be continued indefinitely at a dose of 75 to 162 
mg. (Level of Evidence: B)” (ACH/AMA, 2009). DES are useful as an alternative to 
BMS to reduce the risk of restenosis in cases in which the risk of restenosis is increased 
and the patient is likely to be able to tolerate and comply with prolonged dual antiplatelet 
therapy (DAPT) (Levine, 2011). BMS should be used in patients with high bleeding risk 
or an inability to comply with 12 months of DAPT, whether for economic reasons or 
other reasons (ACCF, 2011). Due to limited data on women and racial/ethnic minorities 
receiving percutaneous coronary intervention (PCI), there is little conclusive evidence of 
the safety and effectiveness of DES stents among racial/ethnic minorities. Black race 
emerged as a strong predictor of definite VLST even after multivariable analysis and 
adjustment for median income and clopidogrel compliance (Collins et al., 2010), 
suggesting that race needs to be examined further. A recent follow-up study using the 
National Cardiovascular Registry found that Black and Hispanic patients undergoing PCI 





However, previous studies have produced conflicting results for PCI outcomes in black 
and white patients (Berger et al., 2004; Collins et al., 2010; Marks et al., 2000; Maynard 
et al., 2001; Pradhan et al., 2008; Slater et al., 2003). It is possible that higher CHD 
outcomes may vary by race due to a higher prevalence of comorbidities in racial/ethnic 
minority groups (Khambatta, Seth, Rosman, & Share, 2011).  
Women have a higher risk of bleeding and excess dosing of CHD treatment 
(Alexander et al., 2006). Adverse drug reactions tend to occur more often in women and 
are most likely caused by inherent sex-differences in pharmacodynamics, such as body 
mass index and reduced glomerular filtration rate (Anthony & Berg, 2002). Changes in 
circulating estrogen levels during the menstrual cycle, pregnancy, or hormone 
replacement therapy can also affect CHD.   
The MPCD dataset offers an opportunity to examine a large, nationwide dataset 
of medical claims that includes racial/ethnic minorities and females who underwent stent 
implantation. This thesis examines racial and gender differences in the safety and 
effectiveness of DES and BMS and can inform methodological approaches to treatment 
outcomes for safety and efficiency by race and gender using diverse data sources. The 
MPCD was used to detect signals and evaluate post-market data for medical products 
related to racial/ethnic minority health and women’s health that have not been used in the 





IV. RESEARCH DESIGN AND METHODS 
Overall Study Design 
This study compared health outcomes in a representative sample of healthcare 
beneficiaries who received a DES or BMS. The study design was a retrospective cohort 
study using a representative sample of Medicare, Medicaid, and private insurance 
beneficiaries who were older than 41 years of age and who received coronary stenting 
between January 2007 and December 2010. This retrospective cohort used a follow-up 
period of 2 to 4 years until the end of data collection in December 2010. Outcomes were 
measured using relevant International Classification of Diseases, Ninth Revision, Clinical 
Modification (ICD-9-CM) and Current Procedural Terminology (CPT) codes in claims 
data from the Multi-Payer Claims Database (MPCD) (see Appendix A).  
In order to fulfill Study Aim 1, descriptive statistics were used to establish 
baseline characteristics for both stent type groups. To fulfill Study Aims 2 and 3, a 
comparative analysis of DES versus BMS for groups was stratified by gender 
(male/female) and race (white/black/Hispanic/Asian). Figure 2 depicts the exposure and 
outcome variables involved in treatment for CHD that were assessed in this project.  
Data Source and Validation 
The MPCD is a nationwide sample of Centers for Medicare & Medicaid Services 
(CMS) Chronic Conditions Warehouse (CCW) data and Normative Health Information 
(NHI) private-payer data collected between January 1, 2007, and December 31, 2010. 
The CCW sample contains all claims from a 15% random sample of Medicare 
beneficiaries. These data were compared with data from the U.S. Census Bureau Profiles 













FIGURE 1. DIAGRAM 




and gender distribution of the total US population, with around 90% of the sample being 
represented by White, Black, and Hispanic races and were evenly split by male and 
female. As for age, the NHI subset of the data was the most representative of the US 
population, with 57.9% patients under 40 years of age, compared to 53.8% of the US 
population that is under 40 (OptumInsight, 2013). The analytic dataset includes a sample 
of coronary stent recipients among all payers within the NHI database, a geographically 
and demographically distributed sample of commercial claims. The vast majority of NHI 
data is group coverage. All of the outcome variables studied were categorical variables 
and were paired to the date of the event. This retrospective analysis is based on claim 
codes entered into the system by healthcare physicians, nurses and secretaries. 





A sample of 217,654 Medicare, Medicaid, and private health insurance beneficiaries 
continuously enrolled for six months, at least 41 years of age, who received a primary 
diagnosis of non-chronic coronary artery disease in a native vessel (ICD-9 code 414) and  
 
FIGURE 2. SCHEMATIC OF EXCLUSION AND INCLUSION CRITERIA FOR INDIVIDUALS IN THE MPCD. 
 
underwent a stent implantation between January 2007 and December 2008 was identified 
from the MPCD database. Patients who underwent both DES implantation and BMS 
implantation procedures were excluded, as seen in Figure 2. 
Main Exposure Variable: Stent Type  
The exposure variable for this study is stent type, either BMS or DES. Patients 





Healthcare Common Procedure Coding System codes. The type of stent implanted for 
each patient was identified as having received either BMS (36.06, C1876, C1877, 92980, 
92981) or DES (36.07, C1874, C1875, G0290, G0291) using ICD-9 and HCPCS codes 
and matched to each individual by patient identifier number.  The initial stent 
implantation was noted by the date associated with the initial stent procedure claim code. 
Consecutive procedures occurring within 7 days of one another were considered part of 
the same clinical episode. Duplicates were removed if multiple procedures were included 
in the procedures file for a single patient identifier number. Of these patients, 68,586 
received at least one bare-metal stent and 149,068 received at least one DES stent 
between July 2007 and December 2008. Univariate analyses were conducted to compare 
BMS and DES patients using t-tests and chi-square tests in SAS 9.3. A significance level 
of 0.05 was used for all analyses. 
Confounders 
Information on coronary artery disease risk factors was collected from diagnosis 
files of patients included in MPCD dataset. Demographic information (i.e., age, gender, 
race) was collected from demographic files of patients in the MPCD and matched to each 
individual using a unique patient identifier number. Confounders were included in the 
Cox proportional hazards model if they altered the coefficient of the main variable by 
more than 10 percent. Effect modification was assessed by testing for interaction terms. 
Age was stratified into five year increments. Race was stratified into five categories: 
“White”, “Black”, “Hispanic”, “Asian”, “Other”. Only one race could be selected per 
patient in the MPCD; therefore, there may be under-reporting of Hispanics.  Variables 





hypertension, ischemia, high cholesterol, and previous AMI. These binary variables were 
identified by matching the associated ICD-9 code with the unique patient identifier 
number. 
Time-to-CHD Event Variables 
For study aims 1-3, beneficiaries were followed for 2 to 4 years through 
December 2010. The incidence of CHD events among beneficiaries with a coronary stent 
implanted was examined by stent-type, and stratified by race (aim 2) or gender (aim 3). 
CHD events included death, AMI, PCI, and CABG.  AMI (410.X1), CABG (36.10-
36.19), and repeat or PCI (36.00, 36.06, 36.07, 36.09) were identified by ICD-9 CM 
diagnosis codes. Time-to-event variables were paired to each patient by calculating the 
time between. A censoring variable was also included to censor out any patients that were 
free of the event during the duration of the study. Surgeons use CABG, a type of surgery 
that improves blood flow to the heart to treat people who have severe CHD. During 
CABG, a healthy artery or vein from the body is connected to the blocked coronary artery 
to allow oxygen-rich blood to flow to the heart muscle.  PCI consists of angioplasty and 
stenting. Angioplasty is a procedure to open narrowed or blocked coronary arteries and is 
typically followed by the implantation of a stent. Within the MPCD, the first angioplasty 
or stenting after the initial stent procedure was included as a CHD outcome. Data were 
right-censored for patients who continued to be enrolled in the MPCD throughout the 






Study Aim 1: Baseline characteristics were compared between the group 
receiving DES versus BMS stents using a χ2 test for categorical variables and a t test for 
continuous variables. The normality distribution was tested using the univariate analysis 
in SAS and looking at the normal probability plot (see Appendix C). This information 
was used to determine whether there was a significant difference in age, race, gender, and 
diagnoses distributions between patients receiving DES and patients receiving BMS. This 
was crucial to determining whether the baseline characteristics of both stent groups are 
comparable and which covariates needed to be adjusted for in the Cox proportional 
hazards model. Among the beneficiaries who received a stent procedure, a Kaplan Meier 
analysis at 2-year follow-up was used to estimate the CHD event-free probability (repeat 
PCI, CABG, AMI) by stent type (BMS and DES).  
Study Aims 2 and 3: Among the beneficiaries who received a stent procedure, a 
Kaplan Meier analysis at 2-year follow-up was used to estimate the probability of CHD 
events (repeat PCI, CABG, AMI) by stent type, stratified by gender (female and male) or 
race (white/Black/Asian/Hispanic/other).  Potential confounders included patient 
demographic variables (e.g., race, gender) and comorbidities (e.g., ischemia, high 
cholesterol, hypertension, previous AMI).  
A Cox proportional hazards model was used to conduct a multivariate model 
adjustment. Significant covariates to include in the model were chosen by identifying the 
variables that produced a greater than 10% deviation from unadjusted hazard ratio. The 
model included covariates such as demographic variables (i.e., gender and race) as well 
as those comorbidities that were significantly different between stent type groups as seen 





multivariate cox proportional hazards model, proportionality was tested for all covariates 
(See Appendix C). Analyses were also stratified by age group because the proportionality 
assumption did not hold for age, especially ages below 41. 
Human Subjects Research 
The MPCD was compiled using data from the NHI, Medicare, and Medicaid with 
funding from the American Recovery and Reinvestment Act. The Assistant Secretary for 
Planning and Evaluation worked with the Centers for Medicare and Medicaid Services to 
manage the generation of the MPCD and contract the work to OptumInsight. When 
compiling the MPCD, OptumInsight kept patient identifier numbers anonymous and 
grouped individuals into 5 year age cohorts for ease of reporting and to meet HIPAA 
privacy regulations. This study was deemed Health Insurance Portability and 
Accountability Act (HIPAA)-compliant and exempt from Institutional Review Board 
(IRB) review at the University of Maryland due to the anonymity of the patient identifiers 
in this dataset (see Appendix B).  
V. RESULTS 
Study Sample 
Of the patients included in this sample, 63.4% were male, 39.9% had been 
diagnosed with diabetes, 52.8% with high cholesterol, 94.7% with ischemia, and 59.9% 
with hypertension. Patients receiving DES were slightly younger (average age of 71.2 
years); were 63.9% male; and had a significantly higher percentage of Hispanics or 
Asians compared to patients receiving BMS (Table 1). Compared to patients who 





cholesterol, a history of myocardial infarction, or ischemia; and less likely to have 
hypertension.  Of note is that observed differences in baseline demographic statistics by 
stent type are very small but statistically significant due to the large sample size. In the 
SAS univariate procedure, P-P, and Q-Q plots (see Appendix C), the data points do not 
seriously deviate from the fitted line, indicating that the continuous variable, age, is 
normally distributed. 
TABLE 1. DEMOGRAPHIC CHARACTERISTICS OF MPCD STENT PATIENT SAMPLE. 
 
TABLE 2.  COMORBIDITIES IN STENT PATIENT SAMPLE. 
Health Characteristics BMS (n = 68,586) DES (n = 149,068) p 
  n % n %   
Diabetes 31,013 40.3% 70,078 39.7% 0.0114 
High Cholesterol 39,432 51.2% 94,362 53.5% < 0.0001 
Hypertension 48,262 62.7% 103,540 58.7% < 0.0001 
Ischemia 71,526 92.9% 168,466 95.5% < 0.0001 
Prior AMI 51,886 67.4% 128,777 73.0% < 0.0001 
Prior AMI - Within 30 
Days of Stent 480 0.6% 1,011 0.6% 0.1229 
Prior CABG 1,244 1.6% 2,727 1.6% 0.1978 
 
Demographic Characteristics BMS (n = 68,586) DES (n = 149,068) p 
Mean Age in Years ± SD 73.4 ± 9.9 71.2 ± 10.3 < 0.0001 
Age Range          41-85 years 41-85 years  
Male 47,789 62.1% 112,769 63.9% < 0.0001 
Race         
White 58,842 85.8% 127,457 85.5%  < 0.0001 
Asian 820 1.2% 2,633 1.8%  
Black 6,254 9.1% 12,248 8.2%  
Hispanic 1,810 2.6% 4,859 3.3%  





Of the 142,816 who completed at least a 1-year follow-up, a total of 22,327 
(15.8%) patients underwent a follow-up PCI; 3,372 (2.4%) underwent CABG; and 6,028 
(4.2%) suffered from an AMI.  
 Overall, the event-free probability of repeat stent implantation, follow-up CABG, 
and AMI was higher among DES recipients than BMS recipients. Unadjusted Kaplan-
Meier event curves depicted below show an increased CHD event-free probability for  
 
DES as compared to BMS for each CHD event of interest (Figure 3). DES was associated 
with a significant cumulative hazard reduction in repeat PCI, AMI, and CABG.  
As seen in Table 3, females were at increased hazard of AMI and decreased 
hazard of CABG compared to males. Compared to Whites, Black patients were at 
log-rank p-value < 0.001 log-rank p-value < 0.001 
log-rank p-value < 0.001 
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increased hazard of AMI and Asian patients were at decreased hazard of AMI. No 
significant interaction was found between stent type and gender or race.  
TABLE 3. COVARIATE-ADJUSTED HAZARDS RATIOS [95% CONFIDENCE INTERVALS].1 
  AMI CABG Repeat PCI Interaction Term 
Unadjusted 0.799 (0.764 , 0.835) 0.643 (0.606 , 0.683) 0.918 (0.896 , 0.940)  
Adjusted 0.808 (0.772 , 0.847) 0.627 (0.590 , 0.666) 0.909 (0.887 , 0.931)  
Gender  
(Ref = Male)       
0.7190 (P =0.3965) 
Female 1.053 (1.006, 1.103) 0.823 (0.873 , 0.876) 0.997 (0.973 , 1.021)  
Race  
(Ref = White)      
6.5156 (P =0.1638) 
Black 1.325 (1.234, 1.423) 0.960 (0.860 , 1.071) 1.079 (1.036, 1.123)  
Hispanic 1.044 (0.918, 1.187) 0.899 (0. 749, 1.079) 0.896 (0.835, 0.962)  
Asian 0.809 (0.644, 0.987) 0.835 (0.644 , 1.083) 0.965 (0.879 , 1.060)  
Other 1.233 (1.023, 1.487) 1.149 (0.894, 1.476) 1.079 (1.132 , 1.370)  
 
The Cox proportional hazards model was stratified by gender and race to fulfill 
aims 2 and 3. A decreased hazard of CABG was seen across all races and both genders, but 
a benefit of DES was seen only across Whites in AMI and repeat PCI and only across 
Asians in AMI. The stratified analysis in Table 4 suggests that gender and race are effect 




1 Cox Proportional Hazards for DES compared to BMS. Adjusted for comorbidities: ischemia, high blood 
pressure, high cholesterol, and previous AMI. 
19 
 
                                                                
 
 







Once adjusted for race and gender, the Cox proportional hazards model produced 
estimates showing association between stent type and all CHD outcomes. Results were 
stratified by age because not all age groups passed the test of proportionality, specifically 
those patients under the age of 41 (see Appendix D). The hazard ratio for DES compared 
with BMS was 0.811 (95% confidence interval [CI]: [0.774 , 0.849]) for AMI, 0.627 (CI: 
[0.590, 0.666]) for CABG, and 0.910 (CI: [0.888, 0.933]) for a repeat PCI (Table 5). 
There was a significant event-free benefit of DES over BMS in those 66 and over for 




2 Cox Proportional Hazards for DES compared to BMS. Adjusted for comorbidities: ischemia, high blood 
pressure, high cholesterol, and previous AMI and stratified by gender and race. 
  AMI CABG Repeat PCI 
Unadjusted 0.799 (0.764 , 0.835) 0.643 (0.606 , 0.683) 0.918 (0.896 , 0.940) 
Adjusted 0.808 (0.772 , 0.847) 0.627 (0.590 , 0.666) 0.909 (0.887 , 0.931) 
By Gender       
Male 0.791 (0.748 , 0.838) 0.601 (0.561 , 0.644) 0.908 (0.881 , 0.935) 
Female 0.816 (0.761 , 0.876) 0.677 (0.613 , 0.747) 0.893 (0.860 , 0.928) 
By Race      
White 0.806 (0.766 , 0.848) 0.623 (0.584 , 0.664) 0.909 (0.886 , 0.934) 
Black 0.874 (0.761 , 1.002) 0.797 (0.643 , 0.988) 0.927 (0.856 , 1.005) 
Hispanic 0.828 (0.629 , 1.090) 0.510 (0.354 , 0.736) 0.865 (0.742 , 1.009) 
Asian 0.502 (0.333 , 0.755) 0.480 (0.282 , 0.818) 0.830 (0.672 , 1.025) 
Other 0.876 (0.592 , 1.296) 0.469 (0.285 , 0.773) 0.996 (0.811 , 1.222) 
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TABLE 5. COVARIATE-ADJUSTED HAZARDS RATIOS [95% CONFIDENCE INTERVALS], STRATIFIED BY AGE.3 
  AMI CABG Repeat PCI 
Unadjusted 0.799 (0.764 , 0.835) 0.643 (0.606 , 0.683) 0.918 (0.896 , 0.940) 
Adjusted 0.811 (0.774 , 0.849) 0.627 (0.590 , 0.666) 0.910 (0.888 , 0.933) 
By Age Group       
41-45 0.825 (0.484 , 1.406) 0.686 (0.354 , 1.331) 0.863 (0.638 , 1.168) 
46-50 1.218 (0.833 , 1.781) 0.541 (0.375 , 0.778) 1.058 (0.876 , 1.278) 
51-55 0.914 (0.711 , 1.174) 0.569 (0.432 , 0.751) 0.915 (0.800 , 1.047) 
56-60 0.867 (0.703 , 1.068) 0.610 (0.484 , 0.768) 0.911 (0.817 , 1.017) 
61-65 0.957 (0.803 , 1.142) 0.510 (0.418 , 0.623) 0.841 (0.767 , 0.921) 
66-70 0.633 (0.554 , 0.723) 0.588 (0.502 , 0.688) 0.815 (0.762 , 0.871) 
71-75 0.768 (0.692 , 0.854) 0.571 (0.502 , 0.648) 0.899 (0.852 , 0.948) 
76-80 0.758 (0.679 , 0.845) 0.584 (0.509 , 0.670) 0.908 (0.858 , 0.961) 
81-85 0.879 (0.809 , 0.954) 0.703 (0.615 , 0.805) 0.946 (0.903 , 0.990) 
 
  
3 Cox Proportional Hazards for DES compared to BMS. Adjusted for comorbidities: ischemia, high blood 
pressure, high cholesterol, and previous AMI and stratified by age. 
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In this retrospective study of health insurance beneficiaries receiving a stent, we 
compared results using a Cox proportional hazards modeling approach to account for 
confounding effects of covariates. The findings from this study of beneficiaries are 
consistent with other observational studies that found improved CHD outcomes (i.e., 
decreased rates of repeat PCI, CABG, and AMI) for patients with DES as compared to 
BMS (Federspiel et al., 2012; Malenka et al., 2008). However, since mortality data were 
missing in the MPCD database and death could not be analyzed as a CHD outcome, no 
comparisons could be made with results from other studies regarding event-free 
probability. 
Observed differences in baseline demographic statistics by stent type are very 
small but may be statistically significant due to the large sample size.   
Stratifying by race revealed an increased event-free probability of DES over BMS 
in looking at AMI as a health outcome only among Whites and Asians. In future studies, 
it would be interesting to look into why there is no clear benefit of DES over BMS in 
Blacks and Hispanics. This study did not take into account DAPT adherence or a socio-
economic variable (e.g., zip code, health insurance type) but further analysis into these 
variables in the MPCD may provide additional information. As for gender, a significantly 
lower hazard of AMI, CABG, and repeat PCI was seen for both genders.   
One limitation of using administrative claims data is that residual confounding 
may exist due to lack of detail on the type and number of stents implanted (e.g., not 
enough information to distinguish multiple stents in one procedure versus multiple 
procedures) and inaccurate insurance claim codes (e.g., confusion with HCPCS and ICD-





observational and dependent on healthcare staff responsible or entering the data, the way 
an insurance claim is interpreted and entered into the system could lead to varying levels 
of accuracy and completeness from healthcare center to healthcare center. The MPCD 
dataset was validated against data from the US Census Bureau to account for 
underreporting or misclassification of events (OptumInsight, 2013). Previous studies 
using a similar claims database lacked detailed information about patient clinical 
characteristics and emphasized the importance of adjusting for baseline characteristics 
(Douglas et al., 2009; Epstein, Polsky, Yang, Yang, & Groeneveld, 2011).    
A major limitation is that mortality records were incomplete and survival rates could 
not be calculated for DES versus BMS. Because this was a retrospective study, I was 
unable to request additional information on variables of interest and analyze in more 
detail.  For example, details on where the stent was placed in the vasculature and how the 
stent was implanted were incomplete. With more detailed insurance claim codes, it would 
be possible to decipher between single stent and multi-stent procedures. Also, the type of 
drug being eluted by DES is not specified in the MPCD. As technology improves and 
DES become more diverse (i.e., Paxitol-eluting, Sirulimus-eluting), significant 
differences in CHD outcomes may result from these different types of stents.  
Future studies should include cost effectiveness studies to address the increased 
cost of DES due to additional manufacturing costs to coat the stent with the drug polymer 
and research and development. They should also consider implementing a data collection 
method that allows for proper matching to death records, especially since the CHD 
outcomes of interest in this study could not cover all other possible outcomes (i.e., VLST, 





examined include zip code and other proxies for socioeconomic status that may indicate 
that access to care is an important factor to successful outcomes from stent implantation. 
Since the MPCD contains a code for the type of health insurance, it would be interesting 
to explore health insurance type and examine differences in health outcomes between 
commercial and public health insurance carriers. Furthermore, since adherence to DAPT 
is so critical to ensure positive health outcomes after DES implantation, it would be 
beneficial to analyze drug adherence rates. This may explain observed differences 
between races as well as by age. For example, older patients may have a more difficult 
time remembering to take their daily medications. 
Other analytic approaches could be considered by future studies, such as 
propensity score matching, to estimate the effect of BMS and DES while accounting for 
covariates.  Propensity score matching may also take into account covariates that reduce 
the potential for bias in treatment (BMS vs. DES) selection since stent guidance is at the 
discretion of the treating physician. It would be interesting to see if insurance type (i.e., 
private versus public) affects the decision to implant BMS and DES. Once a few 
additional statistical methods are explored, it would be beneficial to compare these 
measures to clinical outcomes from other study types to evaluate and validate the 
potential surveillance utility of this dataset. 
Conducting an observational analysis using claims data provides a better 
understanding of BMS versus DES utilization across beneficiaries at the population level 
at a significantly lower cost and greater generalizability than randomized clinical trials. 
The MPCD dataset that was used in this analysis is readily available, providing the 





study provided similar results to existing studies, the MPCD may be valid for quick 
adverse effect surveillance. With quicker surveillance, negative health outcomes could be 
detected faster than current methods and health complications nationwide could be 
avoided.   In order to validate the MPCD as a tool for detecting adverse effects, these 
surveillance studies should look on the same outcome (i.e., AMI, repeat stent) and the 





V. Public Health Significance 
More than 15 million, or six percent, of Americans have been diagnosed with 
CHD (Mozaffarian et al., 2015). Coronary atherosclerosis is responsible for more than 9 
million ambulatory care visits and more than 700,000 hospitalizations. Among adults 
younger than 65 years, Medicaid beneficiaries were more likely to be diagnosed with any 
type of heart disease, compared to those with private insurance or uninsured  (Pleis, 
Ward, & Lucas, 2009).  It is estimated that 22 per 10,000 adults receive a stent, with even 
higher rates for the elderly (73 per 10,000 among 65 and older) (Kochanek, Xu, Murphy, 
Minino, & Kung, 2012).  
Given how common coronary stents are, it is important to understand the 
comparative effectiveness and safety of these devices. This information will be useful for 
physicians and patients to make informed health care decisions.  This study addresses the 
need for evaluation of comparative performance (effectiveness and safety) between BMS 
and DES that are already on the market among a nationwide sample. Previous nationwide 
comparisons between these two types of stents have only included Medicare beneficiaries 
or only included managed care beneficiaries (Douglas et al., 2009; Federspiel et al., 2012; 
Meadows et al., 2012), whereas the MPCD includes private insurance claims among 
younger patients. The use of claims data enables low-cost, observational analyses that 
evaluate real-world usage patterns and populations on a regular basis at a reasonable cost.  
This dataset could be applied to improving post-market surveillance of medical 
devices.  In the case of BMS versus DES, this dataset produced comparable results to 
other retrospective studies on Medicare claims. With the coverage of Medicare, Medicaid 





to provide insight into long-term adverse effects that haven’t been explored previously; in 
the case of stents, onset of ST and VLST were explored. In order to incorporate regular 
use of this database for monitoring of adverse events, studies on health outcomes could 
be explored for other medical devices of interest. Once it is established that statistical 
measures obtained from the MPCD are reliable, measures could be taken to shorten the 
turnaround time between data collection and analysis so that adverse effects can be 
detected within a few weeks. This would be useful for monitoring adverse effects of new 
medical devices when they are introduced to the market. Conditions that are clearly 
identified in insurance databases by HCPCS and ICD-9 codes would lend themselves 
well to use of this type of surveillance. There would have to be an emphasis on 
maintaining complete records of patients (e.g., ensuring that all comorbidities are 
included in the patient record). This database would require additional resources to 
continuously update, maintain, and monitor. While there would be an increase in cost to 
more rapidly compile this insurance claim data, the MPCD would offer a long-term 
benefit of being able to collect these measures and take a device off the market in time to 





VI. MPH COMPETENCIES ADDRESSED IN THESIS 
I addressed the following MPH competencies throughout my thesis: 1-14. Figure 
3 illustrates the complete list of the competencies for a MPH in Epidemiology and those 
that were addressed through my internship and thesis. 
Table 6. Competencies for MPH in Epidemiology Internship/Thesis 
Competencies for MPH in Epidemiology Internship/Thesis Internship Thesis 
1. Demonstrate the importance of epidemiology for informing 
scientific, ethical, economic, and political discussion of health 
issues. 
X X 
2. Assess a public health problem in terms of magnitude, person, 
time and place. 
X X 
3. Distinguish among the basic terminology and definitions of 
epidemiology.   
X X 
4. Discriminate key sources of data for epidemiological purposes.   X X 
5. Calculate basic epidemiology measures.   X X 
6. Identify the principles and limitations of public health screening 
programs.   
X X 
7. Evaluate the strengths and limitations of epidemiologic reports.  X X 
8. Draw appropriate inferences from epidemiologic data.   X X 
9. Explain criteria for causality.    X 
10. Calculate advanced epidemiology measures.    X 
11. Communicate epidemiologic information to lay and professional 
audiences. X X 
12. Compare basic ethical and legal principles pertaining to the 
collection, maintenance, use and dissemination of epidemiologic 
data. 
X X 
13. Design, analyze, and evaluate an epidemiologic study.   X X 
14. Design interventions to reduce prevalence of major public health 
problems.    X 
15. Demonstrate program administration and organizational 







 APPENDIX A. ICD-9 AND HCPCS CODES TO BE USED IN ANALYSIS [NCHS, 2010] 
Stent Implantation  





0045 Insertion of one vascular stent 
0046 Insertion of two vascular stents 
0047 Insertion of three vascular stents 
0048 Insertion of four or more vascular stents 
0055 
Insertion of drug-eluting stent(s) of other peripheral 
vessel(s) 
0060 
Insertion of drug-eluting stent(s) of superficial femoral 
artery 
0063 Percutaneous insertion of carotid artery stent(s) 
0064 
Percutaneous insertion of other extracranial artery 
stent(s) 
0065 Percutaneous insertion of intracranial vascular stent(s) 
0066 Percutaneous transluminal coronary angioplasty [PTCA] 
3606 Insertion of non-drug-eluting coronary artery stent(s) 





Transcatheter placement of an intracoronary stent(s), 
percutaneous,with or without other therapeutic 
intervention, any method; single vessel. 
92981 each additional vessel 
0075T 
Transcatheter placement of extracranial vertebral or 
intrathoracic carotid artery stent(s), including radiologic 
supervision and interpretation, percutaneous; initial 
vessel. 
0076T each additional vessel 
37205 
Transcatheter placement of an intravascular stent(s) 
(except coronary, vertebral, iliac and lower extremity 
arteries), percutaneous; initial vessel 
37206 
Transcatheter placement of an intravascular stent(s) 
(except coronary, vertebral, iliac and lower extremity 
arteries), percutaneous; each additional vessel (List 
separately in addition to code for primary procedure) 
37207 
Transcatheter placement of an intravascular stent(s) 
(except coronary, vertebral, iliac and lower extremity 
arteries), open; initial vessel 
37208 
Transcatheter placement of an intravascular stent(s) 





arteries), open; each additional vessel (List separately in 
addition to code for primary procedure) 
37215 
Transcatheter placement of intravascular stent(s), 
cervical carotid artery, Percutaneous; with distal embolic 
protection 
37216 
Transcatheter placement of intravascular stent(s), 







Transcatheter placement of a drug eluting intracoronary 
stent(s), percutaneous, with or without other therapeutic 
intervention, any method; single vessel 
G0291 
Transcatheter placement of a drug eluting intracoronary 
stent(s), percutaneous, with or without other therapeutic 
intervention, any method; each additional vessel 
C1874 Stent, coated/covered, with delivery system 
C1875 Stent, coated/covered, without delivery system 
C1876 Stent, non-coated/non-covered, with delivery system 






Insertion of non-drug-eluting peripheral (non-coronary) 
vessel stent(s) 
0040 Procedure on single vessel 
0041 Procedure on two vessels 
0042 Procedure on three vessels 
0043 Procedure on four or more vessels 












Acute myocardial infarction of anterolateral wall, episode of care 
unspecified 
41001 Acute myocardial infarction of anterolateral wall, initial episode of care 
41002 
Acute myocardial infarction of anterolateral wall, subsequent episode of 
care 
41010 
Acute myocardial infarction of other anterior wall, episode of care 
unspecified 
41011 Acute myocardial infarction of other anterior wall, initial episode of care 
41012 
Acute myocardial infarction of other anterior wall, subsequent episode 
of care 
41020 
Acute myocardial infarction of inferolateral wall, episode of care 
unspecified 
41021 Acute myocardial infarction of inferolateral wall, initial episode of care 
41022 







Acute myocardial infarction of inferoposterior wall, episode of care 
unspecified 
41031 
Acute myocardial infarction of inferoposterior wall, initial episode of 
care 
41032 
Acute myocardial infarction of inferoposterior wall, subsequent episode 
of care 
41040 
Acute myocardial infarction of other inferior wall, episode of care 
unspecified 
41041 Acute myocardial infarction of other inferior wall, initial episode of care 
41042 
Acute myocardial infarction of other inferior wall, subsequent episode of 
care 
41050 
Acute myocardial infarction of other lateral wall, episode of care 
unspecified 
41051 Acute myocardial infarction of other lateral wall, initial episode of care 
41052 
Acute myocardial infarction of other lateral wall, subsequent episode of 
care 
41060 True posterior wall infarction, episode of care unspecified 
41061 True posterior wall infarction, initial episode of care 
41062 True posterior wall infarction, subsequent episode of care 
41070 Subendocardial infarction, episode of care unspecified 
41071 Subendocardial infarction, initial episode of care 
41072 Subendocardial infarction, subsequent episode of care 
41080 
Acute myocardial infarction of other specified sites, episode of care 
unspecified 
41081 
Acute myocardial infarction of other specified sites, initial episode of 
care 
41082 
Acute myocardial infarction of other specified sites, subsequent episode 
of care 
41090 
Acute myocardial infarction of unspecified site, episode of care 
unspecified 
41091 Acute myocardial infarction of unspecified site, initial episode of care 
41092 






G8006 Acute myocardial infarction: patient documented to have received aspirin at arrival 
G8007 Acute myocardial infarction: patient not documented to have received aspirin at arrival 
G8009 Acute myocardial infarction: patient documented to have received beta-blocker at arrival 
G8010 Acute myocardial infarction: patient not documented to have received beta-blocker at arrival 







 0045 Insertion of one vascular stent 
0046 Insertion of two vascular stents 





0048 Insertion of four or more vascular stents 
3606 Insertion of non-drug-eluting coronary artery stent(s) 








Transcatheter placement of an intracoronary stent(s), percutaneous,with 
or without other therapeutic intervention, any method; single vessel. 










Transcatheter placement of a drug eluting intracoronary stent(s), 
percutaneous, with or without other therapeutic intervention, any 
method; single vessel 
G0291 
Transcatheter placement of a drug eluting intracoronary stent(s), 
percutaneous, with or without other therapeutic intervention, any 
method; each additional vessel 
C1874 Stent, coated/covered, with delivery system 
C1875 Stent, coated/covered, without delivery system 
C1876 Stent, non-coated/non-covered, with delivery system 
C1877 Stent, non-coated/non-covered, without delivery system 









Aortocoronary bypass for heart revascularization, not otherwise 
specified 
3610 (Aorto)coronary bypass of one coronary artery 
3611 (Aorto)coronary bypass of two coronary arteries 
3612 (Aorto)coronary bypass of three coronary arteries 
3613 (Aorto)coronary bypass of four or more coronary arteries 
3614 Single internal mammary-coronary artery bypass 
3615 Double internal mammary-coronary artery bypass 
3616 Abdominal-coronary artery bypass 
3617 Other bypass anastomosis for heart revascularization 
3619 Heart revascularization by arterial implant 
362 Open chest transmyocardial revascularization 
3631 Other transmyocardial revascularization 
3632 Endoscopic transmyocardial revascularization 
3633 Percutaneous transmyocardial revascularization 






33523   
33530   
33533-












APPENDIX C. TESTS OF NORMALITY 





APPENDIX D. TESTS OF PROPORTIONALITY 
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